The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PTIX | -66.69% | -96.1% | -47.55% | -90% |
| S&P | +14.77% | +87.2% | +13.35% | +16% |
Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.
No news articles found for Protagenic Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$12.57K | 0.0% |
| Market Cap | $3.29M | 117.9% |
| Market Cap / Employee | $658.72K | 0.0% |
| Employees | 5 | 0.0% |
| Net Income | -$869.50K | -35.7% |
| EBITDA | -$1,101.29K | -72.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.72M | 157.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $4.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -251.06% | -88.3% |
| Return On Invested Capital | -382.94% | -207.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,395.40K | -651.6% |
| Operating Free Cash Flow | -$1,395.40K | -651.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.76 | -8.34 | -11.14 | -0.80 | -138.05% |
| Price to Tangible Book Value | 22.99 | 9.79 | -11.14 | -0.52 | -102.11% |
| Enterprise Value to EBITDA | -0.83 | -0.39 | -5.76 | -6.92 | 147.76% |
| Return on Equity | -206.4% | -231.9% | -236.1% | -512.8% | 264.82% |
| Total Debt | $0.00K | $0.00K | $4.01M | $4.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
